RxDoctor Payments Data

John Fugate

Optometrist · Hershey, PANPI 1902971419

Payments from drug & device makers

$3,143in general payments, 2019–2025

Across 124 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$741
  • AbbVie$512
  • Alcon$346
  • Coopervision Inc.$307
  • Bausch & Lomb Americas Inc.$245
  • Dompe US, Inc.$160
  • plus $833 from 11 others

What the payments were for

  • Food & beverage$3,12699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,143 in reported general payments places this provider in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,431
Medicare patients
480
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine66$76,732
XiidraLifitegrast30$34,286
LumiganBimatoprost45$26,118
MieboPerfluorohexyloctane/Pf31$24,629
Cyclosporine13$10,779
SimbrinzaBrinzolamide/Brimonidine Tart24$9,572
Loteprednol Etabonate29$5,179
Prednisolone Acetate57$2,939
Brimonidine Tartrate26$2,484
Latanoprost94$1,514
Fluorometholone11$1,493
Doxycycline Hyclate40$579
Timolol Maleate29$526
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$305
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$512$102,850111 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$245$58,91561 claims
AlconSimbrinza$346$9,57224 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$120$5,17929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →